Enhertu delayed HER2-mutant lung cancer progression by a median of six months versus Keytruda plus chemo in a Phase 3 trial. Survival is unresolved.
First-Line Enhertu Delayed HER2-Mutant Lung Cancer Progression by Six Months Over Keytruda Plus Chemotherapy, but Survival Remains Unsettled
by | Sep 17, 2026 | Uncategorized | 0 comments
Recent Comments